01568nas a2200205   4500008004100000245014000041210006900181260000800250300001600258490000700274520081900281100001801100700001801118700002101136700001901157700002401176700002001200700001701220856012501237       2011                        eng d00aPhotoactive RuII-polypyridyl complexes that display sequence selectivity and high-affinity binding to duplex DNA through groove binding0 aPhotoactive RuIIpolypyridyl complexes that display sequence sele  cFEB  a2089–20980 v173 a<p>The duplex-DNA binding properties of a nonintercalating polypyridyl ruthenium(II) complex that incorporates a linear extended ligand with a catechol moiety has been probed with a variety of photo- and biophysical techniques. These studies reveal that the complex groove binds to DNA sequences biphasically, and displays binding constants equivalent to those of high-affinity metallointercalators. The complex also displays preferential binding to AT-rich sequences. Changes in the structure of the coordinated catechol ligand and the incorporation of intercalating ancillary ligands into the complex were found to modulate both the optical-binding response and binding parameters of the system, which indicates that the catechol moiety plays a crucial role in the observed enhancement to binding affinities.</p>1 aGhosh, Amrita1 aDas, Priyadip1 aGill, Martin, R.1 aKar, Prasenjit1 aWalkar, Michael, G.1 aThomas, Jim, A.1 aDas, Amitava  uhttps://library.ncl.res.in/content/photoactive-ruii-polypyridyl-complexes-display-sequence-selectivity-and-high-affinity02518nas a2200277   4500008004100000022001400041245013400055210006900189260007500258300001400333490000700347520153500354653002101889653001501910653001201925653001901937653002601956100001601982700002101998700002102019700001802040700002002058700001702078700001702095856012802112       2015                        eng d  a0947-653900aCytostatic ruthenium(II)-platinum(II) bis(terpyridyl) anticancer complex that blocks entry into sphase by up-regulating p27(KIP1)0 aCytostatic rutheniumIIplatinumII bisterpyridyl anticancer comple  aPOSTFACH 101161, 69451 WEINHEIM, GERMANYbWILEY-V C H VERLAG GMBHcJUN  a9185-91970 v213 a<p>Cytostatic agents that interfere with specific cellular components to prevent cancer cell growth offer an attractive alternative, or complement, to traditional cytotoxic chemotherapy. Here, we describe the synthesis and characterization of a new binuclear Ru-II-Pt-II complex [Ru(tpy)(tpypma)Pt(Cl)(DMSO)](3+) (tpy=2,2:6,2-terpyridine and tpypma=4-([2,2:6,2-terpyridine]-4-yl)-N-(pyridin-2-ylmethyl)aniline), VR54, which employs the extended terpyridine tpypma ligand to link the two metal centres. In cell-free conditions, VR54 binds DNA by non-intercalative reversible mechanisms (K-b=1.3x10(5)M(-1)) and does not irreversibly bind guanosine. Cellular studies reveal that VR54 suppresses proliferation of A2780 ovarian cancer cells with no cross-resistance in the A2780CIS cisplatin-resistant cell line. Through the preparation of mononuclear Ru-II and Pt-II structural derivatives it was determined that both metal centres are required for this anti-proliferative activity. In stark contrast to cisplatin, VR54 neither activates the DNA-damage response network nor induces significant levels of cell death. Instead, VR54 is cytostatic and inhibits cell proliferation by up-regulating the cyclin-dependent kinase inhibitor p27(KIP1) and inhibiting retinoblastoma protein phosphorylation, which blocks entry into Sphase and results in G1 cell cycle arrest. Thus, VR54 inhibits cancer cell growth by a gain of function at the G1 restriction point. This is the first metal-coordination compound to demonstrate such activity.</p>10aantitumor agents10acytostatic10ap27KIP110aplatinum drugs10aruthenium terpyridine1 aRamu, Vadde1 aGill, Martin, R.1 aJarman, Paul, J.1 aTurton, David1 aThomas, Jim, A.1 aDas, Amitava1 aSmythe, Carl  uhttps://library.ncl.res.in/content/cytostatic-rutheniumii-platinumii-bisterpyridyl-anticancer-complex-blocks-entry-sphase-1